Copeptin Levels in Bipolar Disorder Patients During Manic and Remission Phases

A clinical study by İrem İlter compares serum copeptin levels in 50 bipolar disorder patients during manic episodes, 41 of the same patients in remission, and 50 healthy controls. The dataset includes clinical assessments from scales like YMRS, CGI, HDRS, BDFQ, PSQI, ESS, MES, and SRM-II, along with biochemical parameters. The data was last updated on 2026-05-26.

Use Cases

• Evaluate the diagnostic performance of copeptin as a biomarker for manic episodes based on the reported ROC analysis.
• Investigate associations between neuroendocrine markers and patient functionality using the Bipolar Disorder Functioning Questionnaire (BDFQ).
• Analyze relationships between serum copeptin levels and sleep quality metrics from the Pittsburgh Sleep Quality Index (PSQI).
• Study circadian rhythm patterns in bipolar disorder remission using data from the Morningness-Eveningness Scale (MES) and Social Rhythm Metric (SRM-II).
• Model the partial recovery of the vasopressin system by comparing copeptin levels across manic, remission, and healthy control groups.

Strengths

• Includes longitudinal data from the same patients across manic and remission phases (n=41 paired samples).
• Uses multiple validated clinical assessment scales (YMRS, CGI, HDRS, BDFQ, PSQI, ESS, MES, SRM-II).
• Provides specific diagnostic cut-off values from ROC analysis (e.g., 4.01 ng/mL with 90% sensitivity, 84% specificity).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small in scale (113.2 KB), indicating limited scope.

Provenance

Source

İrem İlter via figshare

Collection Method

Clinical study with serum analysis and standardized questionnaires.

Freshness

Last updated 2026-05-26 06:11:40; freshness should be verified.